1

2

3
Rajashekhar Betageri, Charles L Cywin, Karl Hargrave, Mary Ann Hoermann, Thomas M Kirrane, Thomas M Parks, Usha R Patel, John R Proudfoot, Rajiv Sharma, Sanxing Sun, Xiao Jun Wang: Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents. Boehringer Ingelheim Pharmaceuticals, Robert P Raymond, Mary Ellen M Devlin, Alan R Stempel, January 14, 2003: US06506747 (68 worldwide citation)

1-(4-aminophenyl)pyrazoles optionally substituted on the 3- and 5-positions of the pyrazole ring and on the amino group at the 4-position of the phenyl ring are disclosed and described, which pyrazoles inhibit IL-2 production in T-lymphocytes.


4

5
Chen Shirlynn, Mei Xiaohui: Pharmaceutical compositions comprising hepatitis c viral protease inhibitors. Boehringer Ingelheim Pharmaceuticals, RAYMOND Robert P, January 29, 2004: WO/2004/009121 (61 worldwide citation)

Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions include co-solvent s ...


6
Joerg Martin Bentzien, Brian Nicholas Cook, Charles Cywin, Roman Wolfgang Fleck, Ho Yin Lo, Peter Allen Nemoto, Steven S Pullen, Gregory Paul Roth, Roger John Snow, Hidenori Takahashi, Ji Wang, Kevin J Moriarty, Lei Qiao, Michael Winters: Substituted benzimidazole compounds. Boehringer Ingelheim Pharmaceuticals, Michael P Morris, Mary Ellen Devlin, Anthony P Bottino, November 21, 2006: US07138420 (58 worldwide citation)

Disclosed are substituted benzimidazole compounds of formula (I): wherein R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergi ...


7
Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer: Pyrimidine derivatives. Boehringer Ingelheim Pharma & Co KG, Boehringer Ingelheim Pharmaceuticals, Michael P Morris, Mary Ellen Devlin, Philip I Datlow, February 6, 2007: US07173028 (54 worldwide citation)

The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abo ...


8
Steffen Breitfelder, Pier F Cirillo, Thomas A Gilmore, Eugene R Hickey, John R Proudfoot, John R Regan, Alan D Swinamer, Hidenori Takahashi: Compounds useful as anti-inflammatory agents. Boehringer Ingelheim Pharmaceuticals, Robert P Raymond, Anthony P Bottino, Alan R Stempel, March 19, 2002: US06358945 (50 worldwide citation)

Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.


9
Neil Moss, John Robinson Regan: Methods of treating cytokine mediated diseases. Boehringer Ingelheim Pharmaceuticals, Robert P Raymond, Anthony P Bottino, Timothy X Witkowski, July 12, 2005: US06916814 (47 worldwide citation)

Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein.


10
John R Regan, Pier F Cirillo, Eugene R Hickey, Neil Moss, Charles L Cywin, Christopher Pargellis, Thomas A Gilmore: Aromatic heterocyclic compounds and their use as anti-inflammatory agents. Boehringer Ingelheim Pharmaceuticals, Robert P Raymond, Anthony P Bottino, Alan R Stempel, June 27, 2000: US06080763 (44 worldwide citation)

Novel aromatic heterocyclic compounds inhibit cytokines production involved in immunoregulation and inflammation such as interleukin-1 and tumor necrosis factor production. The compounds are therefore useful in pharmaceutic compositions for treating diseases or pathological conditions involving infl ...